- pre-release versions of legislation and / or regulatory guidance – where scientific advice on product development companies promote innovation – assessment of applications for marketing authorization and – information concerning the safety of marketed medicines to better protect public health. – The potential benefits of this exercise are expected to: – accelerate patient access to new and innovative medicines; – resource savings through reduced duplication of assessment and – improved performance and security as a result of the involvement of the best available expertise from both the EU and Japan. Of letters,e.
Also allow us to safety between the EU and JapanThe European Union and Japan will from now on be exchange confidential information exchange confidential information about the authorization and safety of medicines. Continue reading